Roivant Sciences Ltd. (ROIV) financials: revenue, earnings and cash flow
Fiscal 2021–2026 + TTM · from SEC filings · data as of November 13, 2026
Summary
Roivant Sciences’s revenue went from $24M in fiscal 2021 to $8M in fiscal 2026, a decline of about 19.1% a year.
Net income in fiscal 2026 was -$300M, a net margin of -3629.2%; the best year in this period was 2024 with $4.3B.
Over the twelve months to September 30, 2026, revenue was $41M and net income -$344M.
Free cash flow was -$759M in fiscal 2026 and positive in 0 of the 6 years shown.
The diluted share count rose 10% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenue | $41M | $8M | $29M | — | $32M | $55M | $24M |
| Gross profit | — | — | — | — | — | — | — |
| Operating income | -$558M | -$515M | -$1.0B | $4.5B | -$907M | -$1.4B | -$1.1B |
| Net income | -$344M | -$300M | -$172M | $4.3B | -$1.0B | -$845M | -$809M |
| EPS (diluted) | $-0.57 | $-0.54 | $-0.24 | $5.23 | $-1.42 | $-1.26 | $-1.28 |
| R&D | $712M | $682M | $550M | $440M | $454M | $483M | $237M |
| Revenue growth | — | −71.6% | — | — | −43.0% | +132.3% | — |
Cash flow
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$36M | -$750M | -$839M | -$765M | -$843M | -$678M | -$552M |
| Capital spending | -$3M | -$8M | -$5M | -$1M | -$13M | -$17M | -$6M |
| Free cash flow | -$39M | -$759M | -$844M | -$767M | -$856M | -$695M | -$558M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | $1.3B | $0 | $0 | — | — |
| Stock-based pay | $345M | $346M | $289M | $200M | $218M | $565M | $85M |
Balance sheet
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|---|
| Cash | — | $4.3B | $4.9B | $6.5B | $1.7B | $2.1B | $2.1B |
| Debt | — | $107M | $100M | $488M | $441M | $284M | $245M |
| Equity | — | $4.5B | $4.7B | $6.0B | $1.2B | $1.7B | $1.8B |
| Total assets | — | $5.7B | $5.4B | $7.2B | $2.4B | $2.6B | $2.6B |
| Shares (diluted) | 723M | 694M | 725M | 831M | 713M | 670M | 630M |
Margins and returns
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | -1358.1% | -6235.7% | -3453.3% | — | -2875.9% | -2444.8% | -4500.5% |
| Net margin | -838.2% | -3629.2% | -592.0% | — | -3200.2% | -1528.9% | -3400.9% |
| FCF margin | -96.0% | -9183.5% | -2905.2% | — | -2715.1% | -1257.4% | -2344.8% |
| ROIC | — | -8.8% | -16.6% | 69.3% | -44.8% | -55.0% | -41.4% |
| ROE | — | -6.6% | -3.7% | 72.9% | -87.2% | -51.0% | -45.0% |
Frequently asked questions
What is Roivant Sciences’s annual revenue?
$8M in fiscal 2026 and $41M over the twelve months to September 30, 2026.
How much profit does Roivant Sciences make?
Net income was -$300M in fiscal 2026 (net margin -3629.2%).
Is Roivant Sciences’s revenue growing?
No: revenue fell 71.6% in fiscal 2026 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.